Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

• Status: Not yet recruiting
• Trial end date: 2027-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wenjin Yin

Criteria

Inclusion Criteria:

• Female, age≥18 years old

• ECOG≤2

• Pathologically confirmed primary breast cancer, with pathologically or radiologically confirmed recurrent or metastatic lesions

• HR+/HER2+ or HR-/HER2+ or HR-/HER2-

• At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1

• Disease control (complete response + partial response + stable disease) after salvage treatment

• Expected survival ≥6 months

• Adequate organ function

Exclusion Criteria:

• during pregnancy and lactation

• Patients with central nervous system metastasis